Article
Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.
AIDS (London, England) - 31 Jul 2015
Olson Scott C, Ngo-Giang-Huong Nicole, Beck Ingrid, Deng Wenjie, Britto Paula, Shapiro David E, Bumgarner Roger E, Mullins James I, Van Dyke Russell B, Jourdain Gonzague, Frenkel Lisa M
Abstract excerpt
To prevent mother-to-child-transmission of HIV-1, the 2010 WHO guidelines recommended prenatal zidovudine (ZDV) monotherapy (option A). To determine if ZDV monotherapy selects for HIV resistance in antiretroviral-naive women during pregnancy, specimens from 50 individuals were examined using pyrosequencing. ZDV-resistance mutations were detected at delivery in seven women (14%, 95% confidence interval 6.6-26.5%)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
